Cytogen, Inc., a biotechnology company, develops and sells CTC enrichment systems for cancer diagnosis and treatment in South Korea. It offers Smart Biopsy, an automated CTC enrichment system from blood sample; and cell isolators, IF stainers, cell image analyzers, time laps analyzers, isolation kits, and culture kits. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.

Viral Technologies, Inc., part of CEL-SCI Corp., is a company headquartered in Vienna, VA, that manufactures pharmaceutical and vaccine products.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Laboratoire L Lafon, part of Teva Pharmaceutical Industries Ltd., is a company headquartered in Maison Alfort, France. The firm produces medicinal and pharmaceutical products. Cephalon, Inc., now part of Teva Pharmaceutical Industries Ltd. acquired Laboratoire L Lafon on December 28, 2001 for $450 million.

Pharmaceutical concern

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,500 employees and serves more than 85,000 research and industry customers worldwide through its global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Pharmacia & Upjohn AB is a private company headquartered in Stockholm, Sweden. The firm manufactures pharmaceutical drugs.

UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. their product pipeline is filled with their new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, Autoimmune diseases, and Allergy, along with a portfolio of Animal health diseases. These products are based on their proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies.

Earth Corp. engages in the manufacture, sale, import, and export of pharmaceutical products, quasi-drugs, medical tools, and household products. Its operations are carried out through the Household Products and General Environmental Sanitation segments. The Household Products segment manufactures and sells household insecticide, oral care, bath salts and additives, deodorizers, gardening products, pet supplies, and agricultural and livestock medicine. The General Environmental Sanitation segment includes total health care, pest control, and building maintenance businesses. The company was founded on April 1, 1892 and is headquartered in Tokyo, Japan.

Vitaleech Bioscience NV develops a recom­bi­nant enzyme for the treatment of periodontitis. It offers medicines for the prevention or treatment of periodontitis, a common form of inflammation of the gum tissue that may result in the loss of teeth. The company was founded in 1999 and is headquartered in Bergen op Zoom, the Netherlands.

United States Surgical Corporation manufactures and markets wound closure products and advanced surgical devices. The company’s divisions include the Auto Suture, which offers surgical devices and laparoscopic instrumentation for general and specialty procedures; the Syneture Division that provides sutures and biosurgery products; and USS Sports Medicine, that offers spinal fixation and sports medicine products.

Fujitsu Ltd. engages in the provision of information technology (IT) services. It operates through the following segments: Technology Solutions, Ubiquitous Solutions, and Device Solutions. The Technology Solutions segment provides system integration, consulting, outsourcing, cloud, network, and system support services. It also offers system and network products such as servers, storage systems, software, network management systems, and mobile base stations. The Ubiquitous Solutions segment covers personal computers (PCs). The Device Solutions segment includes electronic components such as semiconductor packages and batteries. The company was founded on June 20, 1935 and is headquartered in Tokyo, Japan.